Stocklytics Platform
Asset logo for symbol BVS
Asset logo for symbol BVS



AI Deep-Learning Forecast (BVS)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Bioventus (BVS) Stocklytics Forecast

Bioventus Inc. (BVS) is an innovative medical device company that focuses on developing and commercializing orthobiologic solutions for musculoskeletal conditions. With a strong commitment to research and development, Bioventus has a robust pipeline of products that address some of the most pressing challenges in orthopedics.

As for the stock price prediction, it is important to note that predicting the future performance of any stock is inherently uncertain and subject to various factors. While AI and machine learning algorithms can provide insights and trends, they should be used as tools to inform investment decisions rather than as definitive predictors.

add Bioventus to watchlist

Keep an eye on Bioventus

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

What is the analyst price prediction for Bioventus (BVS) stock?

Analysts have set a target price of $10.04 for Bioventus (BVS), based on forecasts from 12 analysts. The predicted price range extends from a high of $19 to a low of $2.5. This represents a potential increase of up to 164.99% and a decrease of -65.13% from the current price of $7.17. These forecasts are as of 2021 Mar 08.

What are the analyst ratings for Bioventus (BVS) stock?

Currently, there are no analyst ratings available for Bioventus (BVS), possibly due to insufficient coverage or recent updates.

What is the AI price prediction for Bioventus (BVS) stock?

At present, there is no AI or machine-learning-based price prediction available for Bioventus (BVS) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level